Health Economics›Non-small cell lung cancer squamous›Advanced or metastatic disease first-line

Advanced or metastatic disease first-line

Non-small cell lung cancer squamous · 24 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 17 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Carboplatin and Paclitaxel (CP) and Ipilimumab Variant #01	—	R 788 798	21d	—	13.4 mo	6	R 3 160 481 PFS proxy	1
Carboplatin and nab-Paclitaxel (CnP) and Pembrolizumab Variant #01	—	R 110 213	21d	6.8 mo	18.7 mo	35	R 2 982 456 PFS proxy	5
Carboplatin and Paclitaxel (CP) and Pembrolizumab Variant #01	—	R 84 794	21d	6.8 mo	18.7 mo	35	R 2 886 392 PFS proxy	5
Carboplatin and Paclitaxel (CP) and Ipilimumab, Nivolumab Variant #01 Partial	—	R 81 422	21d	—	15.8 mo	3	R 162 844 PFS proxy	1
Carboplatin and nab-Paclitaxel (CnP) and Atezolizumab Variant #01	—	R 80 722	21d	6.3 mo	—	7	R 515 588 PFS proxy	1
Ipilimumab and Nivolumab Variant #01 Partial	—	R 78 615	42d	~11.5 mo	~29.2 mo	~4	~R 314 461 PFS proxy · indirect	13
Carboplatin and nab-Paclitaxel (CnP) Variant #01	—	R 41 178	21d	5.7 mo	15.2 mo	4	R 164 713 PFS proxy	8
Atezolizumab monotherapy Variant #01	—	R 31 255	21d	20.2 mo	—	2	R 62 509 PFS proxy	1
Carboplatin and nab-Paclitaxel (CnP) and Serplulimab Variant #01 Partial	—	R 28 226	21d	8.3 mo	22.7 mo	35	R 169 355 PFS proxy	2
Carboplatin and nab-Paclitaxel (CnP) and Tislelizumab Variant #01 Partial	—	R 28 226	21d	8.6 mo	—	7	R 169 355 PFS proxy	1
Cisplatin and Gemcitabine (GC) and Necitumumab Variant #01 Partial	—	R 5 458	21d	—	11.5 mo	7	R 32 745 PFS proxy	1
Carboplatin and Gemcitabine (GCb) and Sintilimab Variant #01 Partial	—	R 4 682	21d	5.5 mo	—	39	R 28 092 PFS proxy	1
Carboplatin and Gemcitabine (GCb) Variant #01	—	R 4 414	21d	5.3 mo	12.9 mo	2	R 8 829 PFS proxy	7
Cisplatin and Gemcitabine (GC) Variant #01	—	R 3 933	21d	5.5 mo	9.9 mo	6	R 23 595 PFS proxy	4
Cisplatin and Gemcitabine (GC) and Sintilimab Variant #01 Partial	—	R 3 785	21d	5.5 mo	—	39	R 22 713 PFS proxy	1
Cisplatin and Docetaxel (DC) Variant #05	—	R 3 185	21d	4.2 mo	11.4 mo	3	R 9 556 PFS proxy	2
Docetaxel monotherapy Variant #02	—	R 2 921	28d	—	10.9 mo	8	R 23 372 PFS proxy	1
Carboplatin and Paclitaxel (CP) and Tislelizumab Variant #02 Partial	—	R 2 645	42d	7.6 mo	22.8 mo	5	R 10 579 PFS proxy	2
Carboplatin and Paclitaxel (CP) and Penpulimab Variant #01 Partial	—	R 2 645	21d	7.6 mo	—	5	R 10 579 PFS proxy	1
Carboplatin and Paclitaxel (CP) and Camrelizumab Variant #01 Partial	—	R 2 645	21d	—	—	7	R 15 869 PFS proxy	1
Carboplatin and Paclitaxel (CP) and Sugemalimab Variant #01 Partial	—	R 2 645	21d	9.0 mo	25.3 mo	5	R 10 579 PFS proxy	4
Docetaxel and Nedaplatin Variant #01 Partial	—	R 1 948	21d	—	13.6 mo	6	R 11 686 PFS proxy	1
Carboplatin and S-1 Variant #01 Partial	—	R 1 338	21d	—	~15.2 mo	~4	~R 5 351 PFS proxy · indirect	1
Carboplatin and Paclitaxel (CP) Variant #02	—	R 1 025	21d	4.9 mo	12.9 mo	18	R 18 445 PFS proxy	14

24 of 24 regimens shown